{
    "fund_name": "WisdomTree STOXX Europe Automobiles 2x Daily Leveraged",
    "type": "ETP",
    "ucits": false,
    "replication_method": "synthetic",
    "leverage": true,
    "inverse": false,
    "derivatives": true,
    "swaps": true,
    "complex_factors": [
        "2x daily leverage",
        "Synthetic replication via swaps",
        "Fully collateralised swap structure",
        "Daily reset of leverage factor",
        "High risk profile (7/7)",
        "Complex compounding effects",
        "Counterparty risk exposure"
    ],
    "classification": "complex",
    "supporting_data": "The ETP is classified as complex under MiFID II due to several key factors: 1) It uses synthetic replication via swaps to achieve 2x daily leverage on the STOXX Europe 600 Automobiles & Parts Index, 2) The leverage is reset daily which creates compounding effects that may not be intuitive to retail investors, 3) The product carries a 7/7 risk rating indicating very high potential losses, 4) There is explicit counterparty risk from the swap agreements, 5) The PRIIPs KID contains a 'comprehension warning' indicating the product may be difficult to understand, 6) The recommended holding period is only 1 day, suggesting the product is not suitable for long-term investors. While the product is fully collateralised, the combination of leverage, synthetic replication, and complex compounding effects makes this product unsuitable for retail investors without specialist knowledge.",
    "confidence": 95,
    "counter_argument": "One might argue that the product is fully collateralised and UCITS eligible, which could suggest lower complexity. However, the UCITS eligibility does not automatically make the product non-complex under MiFID II, especially given the significant leverage and synthetic replication components. The daily leverage reset and compounding effects create a risk profile that is materially different from the underlying index, requiring specialist knowledge to understand fully.",
    "risk_profile_alignment": "The product's 7/7 risk rating aligns with its complex classification, as the combination of leverage, synthetic replication, and daily compounding effects creates a high-risk profile that may not be easily understood by retail investors."
}